Browse Items (4 total)

Tags: 103-90-2 (paracetamol), 1095-90-5 (methadone), 1134-47-0 (baclofen), 124-90-3 (oxycodone), 125-56-4 (methadone), 133-16-4 (chloroprocaine), 1333-08-0 (benzocaine), 136-47-0 (tetracaine), 137-58-6 (lidocaine), 15307-79-6 (diclofenac), 15307-86-5 (diclofenac), 15687-27-1 (ibuprofen), 18010-40-7 (bupivacaine), 2017, 2180-92-9 (bupivacaine), 23142-53-2 (methadone), 24847-67-4 (lidocaine), 297-88-1 (methadone), 31121-93-4 (ibuprofen), 38396-39-3 (bupivacaine), 3858-89-7 (chloroprocaine), 40391-99-9 (pamidronic Acid), 437-38-7 (fentanyl), 52-26-6 (morphine), 52485-79-7 (buprenorphine), 527688-20-6 (ibuprofen), 53152-21-9 (buprenorphine), 55750-21-5 (bupivacaine), 56934-02-2 (lidocaine), 57-27-2 (morphine), 57248-88-1 (pamidronic Acid), 66376-36-1 (alendronic Acid), 73-78-9 (lidocaine), 74103-06-3 (ketorolac), 76-42-6 (oxycodone), 76-57-3 (codeine), 76-99-3 (methadone), 79261-49-7 (ibuprofen), 94-09-7 (benzocaine), 94-24-6 (tetracaine), Alendronic Acid/ct [clinical Trial], Alendronic Acid/dt [drug Therapy], Analgesia, Baclofen/ct [clinical Trial], Baclofen/dt [drug Therapy], Beecham E, Benzocaine/ct [clinical Trial], Benzocaine/dt [drug Therapy], Bluebond-Langner M, Bupivacaine/ct [clinical Trial], Bupivacaine/dt [drug Therapy], Buprenorphine/ct [clinical Trial], Buprenorphine/dt [drug Therapy], Candy B, Cerebral Palsy, Chloroprocaine/ct [clinical Trial], Chloroprocaine/dt [drug Therapy], Cochrane Database of Systematic Reviews, Codeine/ct [clinical Trial], Codeine/dt [drug Therapy], Diclofenac/ct [clinical Trial], Diclofenac/dt [drug Therapy], Drug Clearance, Drug Efficacy, Drug Safety, Fentanyl/ct [clinical Trial], Fentanyl/dt [drug Therapy], Functional Status, Howard R, Human, Ibuprofen/ct [clinical Trial], Ibuprofen/dt [drug Therapy], Jones L, Ketorolac/ct [clinical Trial], Ketorolac/dt [drug Therapy], Laddie J, Length Of Stay, Lidocaine/ct [clinical Trial], Lidocaine/dt [drug Therapy], McCulloch R, Methadone/ct [clinical Trial], Methadone/dt [drug Therapy], Morphine/ct [clinical Trial], Morphine/dt [drug Therapy], Neuropathic Pain/dt [drug Therapy], Nociceptive Pain/dt [drug Therapy], Osteogenesis Imperfecta, Oxycodone/ct [clinical Trial], Oxycodone/dt [drug Therapy], Pain Intensity, Pain Severity, Pamidronic Acid/ct [clinical Trial], Pamidronic Acid/dt [drug Therapy], Paracetamol/ct [clinical Trial], Paracetamol/dt [drug Therapy], Priority Journal, Psychological Well-being, Quality Of Life, Randomized Controlled Trial (topic), Rees H, Review, Risk Benefit Analysis, September 2017 List, Tetracaine/ct [clinical Trial], Tetracaine/dt [drug Therapy], Treatment Outcome, Vickerstaff V

Tags: 2016, 52-26-6 (morphine), 53663-61-9 (opiate), 57-27-2 (morphine), 8002-76-4 (opiate), 8008-60-4 (opiate), Adjuvant, Advanced Cancer, Analgesia, Article, Child, Childhood Cancer, Cid Barria L, Constipation, Diagnosis, Drug Efficacy, Drug Safety, Female, Fernandez Urtubia B, Human, Major Clinical Study, Male, Medical Record, Morphine, Morphine/dt [drug Therapy], Nonsteroid Antiinflammatory Agent, Nonsteroid Antiinflammatory Agent/dt [drug Therapy], Oncology 2017 List, Opiate/dt [drug Therapy], Pain Intensity, Pain/dt [drug Therapy], Palliative Therapy, Palma Torres C, Retrospective Study, Revista Chilena De Pediatria, Rodriguez Zamora N, School Child, Sedation, Trevigno Bravo A, Visual Analog Scale

Tags: 2019, alopecia/si [Side Effect], BMJ Paediatrics Open, Bourke B, Broderick A, Child, Clinical Article, Collins A, Devins M, Disease Severity, Drug Efficacy, Drug Substitution, Drug Withdrawal, gabapentin/ae [Adverse Drug Reaction], gabapentin/dt [Drug Therapy], gabapentin/pv [Special Situation for Pharmacovigilance], Gastroenterology, General Paediatrics, Human, Hussey S, hypertransaminasemia/si [Side Effect], Irritability, lethargy/si [Side Effect], Mannion R, muscle twitch, Neurodisability, Neurologic Disease, October 2019 List, Pain, Pain/dt [drug Therapy], Palliative Care, pregabalin/dt [Drug Therapy], pregabalin/pv [Special Situation for Pharmacovigilance], Priority Journal, Retrospective Study, Review, treatment duration, treatment response, vomiting/dt [Drug Therapy], vomiting/si [Side Effect]

Tags: 2023, 2025 SE1 - Oncology, Acute Lymphoblastic Leukemia, Article, Ben-Eltriki M, Bowers A, Bradford N, Brain Tumor, Cancer, cannabinoid/ae [Adverse Drug Reaction], cannabinoid/dt [Drug Therapy], cannabinoid/pv [Special Situation for Pharmacovigilance], chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/pc [Prevention], chemotherapy-induced febrile neutropenia/dt [Drug Therapy], Chhabra M, childhood cancer/dt [Drug Therapy], delta8 tetrahydrocannabinol/dt [Drug Therapy], delta8 tetrahydrocannabinol/pv [Special Situation for Pharmacovigilance], dizziness/si [Side Effect], domperidone/cm [Drug Comparison], domperidone/dt [Drug Therapy], domperidone/pv [Special Situation for Pharmacovigilance], dronabinol/dt [Drug Therapy], dronabinol/pv [Special Situation for Pharmacovigilance], Drug Efficacy, drug formulation, drug indication, Drug Safety, Hematologic Malignancy, Herbert A, Human, Kelly LE, levonantradol/dt [Drug Therapy], levonantradol/pv [Special Situation for Pharmacovigilance], Lymphoma, Me-Linh LE, meta analysis, nabilone/cm [Drug Comparison], nabilone/dt [Drug Therapy], nabilone/pv [Special Situation for Pharmacovigilance], nephroblastoma, Neuroblastoma, Oberoi S, Osteosarcoma, Palliative Therapy, Paul A, prochlorperazine/cm [Drug Comparison], prochlorperazine/dt [Drug Therapy], prochlorperazine/pv [Special Situation for Pharmacovigilance], Rassekh SR, somnolence/si [Side Effect], Systematic Review, xerostomia/si [Side Effect]